LeporH. Medical treatment of benign prostatic hyperplasia. Reviews in Urology2011; 13: 20–33.
3.
KirkbyR, GillingP. Fast facts: benign prostatic hyperplasia.6 ed.Oxford: Health Press Limited;2010.
4.
GroupF. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group. The Prostate1993; 22: 291–9.
5.
LeporH, AuerbachS, Puras-BaezA, NarayanP, SolowayM, LoweF. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Journal of Urology1992; 148: 1467–74.
6.
JacobsenSJ, JacobsonDJ, GirmanCJ, RobertsRO, RhodesT, GuessHA. Treatment for benign prostatic hyperplasia among community dwelling men: The Olmsted County study of urinary symptoms and health status. Journal of Urology1999; 162: 1301–6.
7.
RoehrbornCG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Reviews in Urology2008; 10: 14–25.
8.
KyprianouN, LitvakJP, BorkowskiA, AlexanderR, JacobsSC. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. Journal of Urology1998; 159: 1810–5.
9.
DjavanB, ChappleC, MilaniS, MarbergerM. State of the art on the efficacy and tolerability of alpha(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology2004; 64: 1081–8.
10.
LeporH, HillLA. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy2010; 30: 1303–12.
11.
YuHJ, LinAT, YangSS, TsuiKH, WuHC, ChengCL. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU International2011; 108: 1843–8.
12.
ImperatoJ, GuerreroL, GautierT, PetersonRE. Steroid 5 alpha reductase deficiency in man — inherited form of male pseduhermaphroditism. Science1974; 186: 1213–5.
13.
GormleyGJ, StonerE, BruskewitzRC, Imperato-McGinleyJ, WalshPC, McConnellJD. The effect of finasteride in men with benign prostatic hyperplasia. New England Journal of Medicine1992; 327: 1185–91.
14.
McConnellJD, BruskewitzR, WalshP, AndrioleG, LieberM, HoltgreweHL. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New England Journal of Medicine1998; 338: 557–63.
15.
DebruyneF, BarkinJ, van ErpsP, ReisM, TammelaTL, RoehrbornC. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. European Urology2004; 46: 488–95.
16.
McConnellJD, RoehrbornCG, BautistaOM, AndrioleGLJr, DixonCM, KusekJW. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine2003; 349: 2387–98.
17.
EmbertonM, CornelEB, BassiPF, FourcadeRO, GomezJMF, CastroR. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. International Journal of Clinical Practice2008; 62: 1076–86.
18.
NickelJC, GillingP, TammelaTL, MorrillB, WilsonTH, RittmasterRS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU International2011; 108: 388–94.
19.
LeporH, WillifordWO, BarryMJ, BrawerMK, DixonCM, GormleyG. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New England Journal of Medicine1996; 335: 533–9.
20.
KirbyRS, RoehrbornC, BoyleP, BartschG, JardinA, CaryMM. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology2003; 61: 119–26.
21.
RoehrbornCG, SiamiP, BarkinJ, DamiãoR, Major-WalkerK, NandyI. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. European Urology2010; 57: 123–31.
22.
KaplanSA, McConnellJD, RoehrbornCG, MeehanAG, LeeMW, NobleWR. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 MI or greater. Journal of Urology2006; 175: 217–20.
23.
CornuJ-N, CussenotO, HaabF, LukacsB. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. European Urology2010; 58: 450–6.
24.
TacklindJ, MacDonaldR, RutksI, WiltTJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2009.
25.
RobertG, DescazeaudA, AlloryY, VacherotF, de la TailleA. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia?European Urology Supplements2009; 8: 879–86.
26.
McVaryKT, MonnigW, CampsJLJr, YoungJM, TsengL-J, van den EndeG. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized double-blind trial. The Journal of Urology2007; 177: 1071–7.
27.
McVaryKT, RoehrbornCG, KaminetskyJC, AuerbachSM, WachsB, YoungJM. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of Urology2007; 177: 1401–7.
28.
StiefCG, PorstH, NeuserD, BenekeM, UlbrichE. A randomised placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008; 53: 1236–44.
29.
RoehrbornCG, McVaryKT, Elion-MboussaA, ViktrupL. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. The Journal of Urology2008; 180: 1228–34.
